essence trial semaglutide Phase 3 Trial: in Metabolic Dysfunction-Associated Steatohepatitis Phase 3 ESSENCE trial: Semaglutide

Notice these changes in how food feels in your body

Sodium, potassium, and magnesium all drop when food intake drops

Some users split their weekly dose into two smaller injections

For example, in clinical trials of semaglutide 2.4 mg (Wegovy), nausea occurred in approximately 44% of patients, while rates for tirzepatide and other GLP-1s vary: Nausea : Often described as mild queasiness, particularly after eating, though some patients experience more pronounced nausea Bloating and abdominal fullness : A sensation of delayed digestion or food sitting heavily in the stomach Changes in bowel habits : Constipation affects approximately 15-30% of patients (varying by medication and dose), while some experience diarrhea or alternating patterns [1] [4] Decreased appetite : Beyond simple fullness, many report a fundamental shift in food thoughts, with reduced cravings and less mental preoccupation with eating Some patients report fatigue or low energy , particularly during the initial weeks